Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026
Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026
Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026
Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026
Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026
Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026
Company Drug

Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval

Fineline Cube Apr 28, 2024

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...

Company Drug

HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe

Fineline Cube Apr 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...

Policy / Regulatory

China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement

Fineline Cube Apr 28, 2024

The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...

Company Drug

Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment

Fineline Cube Apr 28, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...

Company Medical Device

Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 28, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023,...

Company

United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships

Fineline Cube Apr 28, 2024

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year...

Company Drug

AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial

Fineline Cube Apr 28, 2024

AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...

Company Policy / Regulatory

Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations

Fineline Cube Apr 28, 2024

Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...

Company Deals

Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation

Fineline Cube Apr 28, 2024

China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...

Company Deals

AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China

Fineline Cube Apr 28, 2024

Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...

Company

Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups

Fineline Cube Apr 28, 2024

Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...

Company

AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I

Fineline Cube Apr 26, 2024

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results...

Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion

Fineline Cube Apr 26, 2024

China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...

Company Deals

Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million

Fineline Cube Apr 26, 2024

Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...

Company Drug

Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy

Fineline Cube Apr 26, 2024

Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies...

Company

Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023

Fineline Cube Apr 26, 2024

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its...

Company

JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva

Fineline Cube Apr 26, 2024

China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...

Company

MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact

Fineline Cube Apr 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...

Company

Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing

Fineline Cube Apr 26, 2024

China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with...

Company Deals

Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round

Fineline Cube Apr 26, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai...

Posts pagination

1 … 321 322 323 … 618

Recent updates

  • Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
  • PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
  • Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
  • Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
  • ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.